AIRNA is developing a new class of RNA editing therapeutics for rare and common diseases. AIRNA’s powerful and flexible RNA editing platform, RESTORE+™, is designed to restore a patient’s health by creating genetic medicines. RESTORE+™ is a systematic advancement of the first published ADAR platform developed by AIRNA’s founders, created to maximize therapeutic properties and address novel targets.
